Hims & Hers $HIMS Lands Eli Lilly Deal: Mounjaro for $149/Month

$HIMS and $LLY have officially buried the hatchet, and the terms are pretty favorable for your waistline. Eli Lilly is now allowing Hims and Hers Health to sell Mounjaro starting at $149 per month and Zepbound at $299 per month directly through the telehealth platform, skipping the awkward detour to Lilly Direct that previously cost Lilly the sale entirely. Bloomberg's Money Minute called it both "surprising and inevitable," which is exactly how the best deals always look in hindsight.

For $LLY, this is a distribution play dressed up as a peace treaty. The old setup forced patients off the Hims platform entirely to access Lilly's obesity drugs, handing the customer relationship to a competitor. Now Lilly gets Hims's distribution reach while keeping brand ownership. The numbers back up why they care: Lilly posted 45.5% revenue growth versus Novo Nordisk's 5.7%, both running at a matching 83% gross margin. That gap is widening, and plugging every distribution leak matters at scale.

For $HIMS, the deal plugs a giant product hole. The company has been riding 28% revenue growth with a 69.5% gross margin, but the GLP-1 space is where the real consumer demand is concentrated. Access to branded Lilly drugs at competitive price points could meaningfully lift conversion and lifetime value. The bull case is simple: Hims becomes the front door for the GLP-1 category for self-pay patients who hate navigating insurance.

The bear case is trickier. Seeking Alpha's quant model rates both $HIMS and $LLY as Hold across valuation, growth, profitability, momentum, and EPS revisions. That is a pretty lukewarm endorsement for a deal that sent both stocks higher. Hims's forward valuation has always been the sticking point, and adding a branded drug distribution arrangement does not automatically fix margin math if acquisition costs spike alongside it.

The broader context here is a GLP-1 access race that is still in early innings. Novo Nordisk's sluggish 5.7% revenue growth versus Lilly's near-50% clip suggests the market is already picking a winner, and Lilly just secured another on-ramp. For self-pay patients priced out of the traditional pharmacy channel, $149 a month for Mounjaro is not nothing, but it is a lot better than $1,000.

The telehealth-pharma cold war lasted about as long as everyone expected: until one side did the math and realized fighting distribution was more expensive than sharing it.